RecruitingPhase 1Phase 2NCT03500731

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure


Sponsor

Paul Szabolcs

Enrollment

8 participants

Start Date

Apr 19, 2018

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying whether patients with severe end-stage lung disease who also have bone marrow failure (meaning their bone marrow is not producing enough blood cells) can safely receive both a lung transplant and a bone marrow transplant at the same time. **You may be eligible if...** - You are between 18 and 60 years old - You have been approved for lung transplant listing due to end-stage lung disease (such as pulmonary fibrosis or COPD/emphysema) - Your bone marrow is also failing — meaning at least one type of blood cell (white cells, red cells, or platelets) is abnormally low - You are considered a poor candidate for long-term immune-suppressing drugs alone **You may NOT be eligible if...** - You do not meet the bone marrow failure criteria listed above - You have not been approved for lung transplant listing - You are outside the 18–60 age range - You are unable to understand and give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALCD3/CD19 negative hematopoietic stem cells

Negative selection for CD3/CD19 will be performed on CliniMACS® depletion device and given at time no less than 8 weeks post lung transplantation

DRUGRituximab

Transplantation Conditioning

DRUGAlemtuzumab

Transplantation Conditioning

DRUGFludarabine

Transplantation Conditioning

DRUGThiotepa

Transplantation Conditioning

DRUGG-CSF

Transplantation conditioning

DRUGHydroxyurea

Transplantation Conditioning


Locations(2)

UPMC Presbyterian

Pittsburgh, Pennsylvania, United States

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03500731


Related Trials